| Detected | Trial | Change |
|---|---|---|
| 2026-06-11 | NCT05633654 Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's… |
Trial sites expanded: 339 -> 350 locations |
| 2026-06-09 | NCT07178730 NeoAdjuvant Therapy Comparing Sacituzumab Govitecan+Pembrolizumab vs. SoC Chemotherapy in… |
Trial sites expanded: 0 -> 26 locations |
| 2026-06-03 | NCT06524544 A Study Comparing the Combination of Pembrolizumab and Sacituzumab Govitean-hziy Versus… |
Trial sites expanded: 140 -> 148 locations |
| 2026-06-02 | NCT05633667 Study of Novel Treatment Combinations in Patients With Lung Cancer |
overall status: "Recruiting" → "Active Not Recruiting" |
| 2026-06-02 | NCT05633667 Study of Novel Treatment Combinations in Patients With Lung Cancer |
Enrollment reduced: 270 -> 192 participants |
| 2026-06-02 | NCT05633667 Study of Novel Treatment Combinations in Patients With Lung Cancer |
Trial sites reduced: 100 -> 89 locations |
| 2026-05-27 | NCT07461454 YL202 Versus Treatment of Physician's Choice in Patients With HR+/HER2- Breast Cancer |
Recruitment opened |
| 2026-05-23 | NCT06524544 A Study Comparing the Combination of Pembrolizumab and Sacituzumab Govitean-hziy Versus… |
Trial sites expanded: 134 -> 137 locations |
| 2026-05-21 | NCT06801834 Study of Sacituzumab Govitecan Versus Standard of Care in Participants With Previously… |
Trial sites expanded: 205 -> 210 locations |
| 2026-05-14 | NCT07492914 Neoadjuvant Sacituzumab Govitecan Plus Tagitanlimab for Resectable Head and Neck Squamous… |
Recruitment opened |
| NCT ID | Title | Condition | Status |
|---|---|---|---|
| Phase 3 | |||
| NCT06431633 | Study of Treatment With Sacituzumab and Zimberelimab for Patients With Lung Cancer… | Lung Diseases | Recruiting |
| NCT06801834 | Study of Sacituzumab Govitecan Versus Standard of Care in Participants With Previously… | Extensive Stage Small Cell Lung Cancer (ES-SCLC) | Recruiting |
| NCT07461454 | YL202 Versus Treatment of Physician's Choice in Patients With HR+/HER2- Breast Cancer | Locally Advanced or Metastatic Breast Cancer | Recruiting |
| NCT05633654 | Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's… | Triple Negative Breast Cancer | Recruiting |
| NCT06524544 | A Study Comparing the Combination of Pembrolizumab and Sacituzumab Govitean-hziy Versus… | Locally Advanced Urothelial Carcinoma | Recruiting |
| NCT06486441 | Study of Sacituzumab Govitecan Versus Treatment of Physician's Choice in Participants… | Endometrial Cancer | Active, Not Recruiting |
| NCT04639986 | Asian Study of Sacituzumab Govitecan (IMMU-132) in HR+/HER2- Metastatic Breast Cancer… | Metastatic Breast Cancer | Active, Not Recruiting |
| NCT05382299 | Study of Sacituzumab Govitecan-hziy Versus Treatment of Physician's Choice in Patients… | Triple Negative Breast Cancer | Active, Not Recruiting |
| NCT04595565 | Sacituzumab Govitecan in Primary HER2-negative Breast Cancer | HER2-negative Breast Cancer | Active, Not Recruiting |
| NCT05089734 | Study of Sacituzumab Govitecan (SG) Versus Docetaxel in Participants With Advanced or… | Non-Small Cell Lung Cancer | Active, Not Recruiting |
| NCT04579224 | Comparing the New Anti-cancer Drug Eribulin With Chemotherapy Against the Usual… | Metastatic Bladder Urothelial Carcinoma | Active, Not Recruiting |
| NCT07178730 | NeoAdjuvant Therapy Comparing Sacituzumab Govitecan+Pembrolizumab vs. SoC Chemotherapy in… | Breast Cancer | Not Yet Recruiting |
| Phase 2 | |||
| NCT06263543 | Sequencing Antibody Drug Conjugates in ER+/HER2 LOW/ULTRA LOW MBC | Breast Cancer | Recruiting |
| NCT06248515 | A Phase II Trial of Sacituzumab Govitecan in Patients With Advanced Thymic Epithelial… | Thymoma | Recruiting |
| NCT05838521 | A Study of Sacituzumab Govitecan (IMMU-132) in Patients With Recurrent or Persistent… | Cervical Cancer | Recruiting |
| NCT07063212 | A Study of Sacituzumab Govitecan in Combination With Cetuximab in People With Head and… | Squamous Cell Carcinoma of Head and Neck | Recruiting |
| NCT03547973 | Study of Sacituzumab Govitecan in Participants With Urothelial Cancer That Cannot Be… | Metastatic Urothelial Cancer | Recruiting |
| NCT05884320 | Phase II Trial of Sacituzumab Govitecan in Recurrent and/or Metastatic Secretory Gland… | Gland | Recruiting |
| NCT04559230 | Sacituzumab Govitecan in Recurrent Glioblastoma | Recurrent Glioblastoma | Recruiting |
| NCT07339059 | Study of Sacituzumab Govitecan With Atezolizumab/Durvalumab as Maintenance Therapy for… | Small Cell Lung Cancer ( SCLC ) | Recruiting |
| NCT04468061 | Sacituzumab Govitecan +/- Pembrolizumab in Metastatic TNBC | Breast Cancer | Recruiting |
| NCT06682728 | Adjuvant Sacituzumab Govitecan and Nivolumab in Muscle-Invasive Urothelial Carcinoma at… | Urothelial Carcinoma | Recruiting |
| NCT04434040 | Atezolizumab + Sacituzumab Govitecan to Prevent Recurrence in TNBC (ASPRIA) | Breast Cancer | Recruiting |
| NCT05601440 | Liquid-biopsy Informed Platform Trial to Evaluate CDK4/6-inhibitor Resistant ER+/HER2… | Breast Cancer | Recruiting |
| NCT03606967 | Testing the Addition of an Individualized Vaccine to Durvalumab and Tremelimumab and… | Anatomic Stage IV Breast Cancer AJCC v8 | Recruiting |